Stem Cell Clinic

Targeted Therapy for Non-Hodgkin Lymphoma: Current Progress and Future Plans – Cancer Therapy Advisor

Non-Hodgkin lymphoma (NHL) is among the most common cancers in the United States. In 2020, an estimated 77,240 Americans will be diagnosed with the disease and about 20,000 people will die from it.1 Seventy-two percent of patients live for at least 5 years after diagnosis.2 However, the success of treatment varies widely across the many subtypes of NHL. Patients diagnosed with diffuse large B-cell lymphoma (DLBCL), the most common subtype, have a 5-year survival rate of 63% for all disease stages combined. By contrast, follicular lymphoma (FL) has a 5-year survival rate of 88% for all stages combined. Patients with mantle cell lymphoma, one of the more difficult-to-treat subtypes, have an average survival time of less than 5 years.3

But the treatment landscape is transforming across the entire spectrum of NHL. Novel immunotherapies and small molecule inhibitors are offering both previously treated and untreated patients entirely new options and new combinations. At the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program, researchers led by Jeremy Abramson, of Massachusetts General Hospital in Boston, provided a compelling overview of these new and upcoming treatments.4 Their overview, published in the ASCO Educational Book, offered a detailed and vital look at the present and future of NHL treatment.

CAR T-cell immunotherapy has been hailed as a major game-changer for some blood cancers.5 For aggressive B-cell lymphomas, such as DLBCL, anti-CD19 chimeric antigen receptor T cells (CAR-T) are a new option for patients who have relapsed following chemoimmunotherapy or autologous stem cell transplant (ASCT). For this patient group, which has a median overall survival of about 4 months, anti-CD19 CAR-T agents have elicited durable remissions in about 40% of patients.5-7 Clinical trial data has led to the approval of axicabtagene, ciloleucel, and tisagenlecleucel by both the US Food and Drug Administration and the European Medicine Agency. CAR T-cells offer curative intent therapy to patients with relapsed DLBCL who are not eligible for stem cell transplant, Dr Abramson told Cancer Therapy Advisor. Previously these patients only had palliative options available.

Some clinicians envision CAR-T as a potential first-line therapy for patients with DLBCL who relapsed after first-line chemoimmunotherapy. These patients, noted Anton Hagenbeek, MD, PhD, professor of Hematology at Amsterdam University Medical Centers, who was not involved with the review paper, represent one of the highest unmet needs in the treatment of lymphoma to date. And Helen Heslop, MD, who directs the Center for Cell and Gene Therapy at Baylor College of Medicine in Houston, Texas, noted that trials for first-line CAR-T therapy are already underway in acute lymphoblastic leukemia. Not everyone sees this potential. First-line treatment in NHL is generally very effective and much less expensive than CAR T-cells, explained Edward Copelan, MD, who chairs the Department of Hematologic Oncology and Blood Disorders at Carolinas Healthcare System in Charlotte, North Carolina, and who was not an author of the review. Though Dr Copelan emphasized that patients at extremely high risk of relapse following standard immunochemotherapy may respond well to CAR-T therapy.

Dr Abramson and co-authors highlighted a difficult conundrum with regard to DLBCL. Although the addition of rituximab to cyclophosphamide, doxorubicin, hydrochloride, and vincristine sulfate (CHOP) chemotherapy is curative for most patients, the number of patients who may be cured after relapse has declined. Thus improvements in second-line therapy are desperately needed. Several clinical trials are currently evaluating anti CD19 CAR-T for primary refractory or early relapsed aggressive B-cell lymphoma compared with traditional salvage therapy or ASCT. The same approach is being studied for relapsed DLBCL patients who are not transplant candidates.

Whether CAR-T therapy will find a place on the first line of care is another current question. The cost and logistics of CAR-T therapy make it unlikely that this approach will replace R-CHOP as the standard initial treatment, Dr Abramson and colleagues noted. I do not think CAR T-cells will replace frontline chemotherapy, Dr Abramson said. However, the authors note that for patients who do not respond well to initial treatment, such an approach may make sense a possibility that is now being examined in the clinical trial setting. Dr Hagenbeek is more certain about the first-line role for CAR-T therapy, based on the dismal prognosis of DLBCL that is refractory to R-CHOP.

On the subject of CAR-T therapy as first-line therapy, the authors pay special attention to so-called double-hit lymphomas (DHLs), also known as double expressor lymphomas. According to a multicenter study published in 2017, R-CHOP is curative for more patients than conventional wisdom has held.9 Clinical trials are currently investigating the use of anti-CD19 CAR-T early for patients who consistently test positive for disease on PET scans during initial therapy, though Dr Abramson and colleagues call for caution with this approach because the prognostic value of PET/CT scans is controversial. Dr Hagenbeek is optimistic about the potential for CAR-T therapy to improve the prognosis for patients with double- and even triple-hit lymphomas, if applied in the first complete, PET-negative metabolic remission. Because these patients have a relatively small tumor load, this approach could, said Dr. Hagenbeek, completely eradicate minimal residual disease. Its the double-hit patients who Dr Copelan sees as the likeliest candidates for first-line CAR T-cell treatment.

Excerpt from:
Targeted Therapy for Non-Hodgkin Lymphoma: Current Progress and Future Plans - Cancer Therapy Advisor

Global Cell Therapy Market (2020 to 2025) – Growth, Trends, and Forecast – ResearchAndMarkets.com – Business Wire

DUBLIN--(BUSINESS WIRE)--The "Cell Therapy Market- Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

The cell therapy market will show rapid growth due to the increasing prevalence of chronic conditions, rising adoption of regenerative medicine and rise in the number of clinical studies pertaining to the development of cellular therapies.

Chronic diseases and conditions are on the rise worldwide. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% by the year 2020. The emerging markets will be hardest hit, as population growth is anticipated be most significant in developing nations. Increased demand for healthcare systems due to chronic disease has thus become a major concern. Healthcare expenditures greatly increase, with each additional chronic condition with greater specialist physician access, emergency department presentations and hospital admissions.

Therefore the increasing prevalence of chronic conditions, government assistance and numerous companies investing heavily in stem cell therapy research and development will help to stimulate the industry growth. The proven effectiveness of cell therapy products coupled with increasingly favorable guidelines pertaining to cell therapy research and manufacturing should positively impact industry growth.

Companies Mentioned

Key Market Trends

Allogeneic Therapies Segment Accounted for the Largest Share in the Cell Therapy Market

Allogeneic therapies rely on a single source of cells to treat many patients. They increase the risk of eliciting an immune response within a patient, and immunosuppressive therapies are sometimes administered in combination with allogeneic products. Therefore there is an increasing inclination of physicians towards therapeutic use of allogeneic therapies coupled with rising awareness about the use of cord cells and tissues across various therapeutic areas is driving revenue generation.

Furthermore, the presence of a substantial number of approved products for clinical use has led to the large revenue share of this segment.

North America is Leading the Cell Therapy Market

North America is estimated to retain the largest share of the market due to the presence of strong regulatory framework in order to promote cellular therapy development, the existence of industry big shots, and high cost of therapies in the U.S. There is also the presence of leading universities that supports the research activities in the U.S. is one of the key factor driving the market for cell therapy in North America.

The Asia Pacific market is also increasing at a rapid rate due to the availability of therapies at lower prices coupled with growing awareness among the healthcare entities and patients pertaining the potential of these therapies in chronic disease management.

Key Topics Covered:

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Increasing Prevalence of Chronic Conditions

4.2.2 Rising Adoption of Regenerative Medicine

4.2.3 Rise in Number of Clinical Studies Pertaining to the Development of Cellular Therapies

4.3 Market Restraints

4.3.1 High Cost of Therapies

4.4 Porter's Five Force Analysis

4.4.1 Threat of New Entrants

4.4.2 Bargaining Power of Buyers/Consumers

4.4.3 Bargaining Power of Suppliers

4.4.4 Threat of Substitute Products

4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

5.1 By Type

5.1.1 Autologous

5.1.2 Allogeneic

5.2 By Therapy

5.2.1 Mesenchymal Stem Cell Therapy

5.2.2 Fibroblast Cell Therapy

5.2.3 Hematopoietic Stem Cell Therapy

5.2.4 Other Therapies

5.3 By Application

5.3.1 Musculoskeletal

5.3.2 Malignancies

5.3.3 Cardiovascular

5.3.4 Dermatology & Wounds

5.3.5 Other Applications

5.4 Geography

5.4.1 North America

5.4.1.1 United States

5.4.1.2 Canada

5.4.1.3 Mexico

5.4.2 Europe

5.4.2.1 Germany

5.4.2.2 United Kingdom

5.4.2.3 France

5.4.2.4 Italy

5.4.2.5 Spain

5.4.2.6 Rest of Europe

5.4.3 Asia-Pacific

5.4.3.1 China

5.4.3.2 Japan

5.4.3.3 India

5.4.3.4 Australia

5.4.3.5 South Korea

5.4.3.6 Rest of Asia-Pacific

5.4.4 Middle-East and Africa

5.4.4.1 GCC

5.4.4.2 South Africa

5.4.4.3 Rest of Middle East and Africa

5.4.5 South America

5.4.5.1 Brazil

5.4.5.2 Argentina

5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Anterogen Co., Ltd.

6.1.2 Tego Science

6.1.3 Chiesi Farmaceutici S.p.A.

6.1.4 Corestem Inc.

6.1.5 Pharmicell Co Ltd.

6.1.6 Fibrocell Technologies Inc

6.1.7 Nipro Corp

6.1.8 MEDIPOST

6.1.9 TiGenix (Takeda Pharmaceuticals)

6.1.10 Stempeutics Research Pvt. Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/9qtcg2

Go here to read the rest:
Global Cell Therapy Market (2020 to 2025) - Growth, Trends, and Forecast - ResearchAndMarkets.com - Business Wire

CC-486 Constitutes Standard of Care for Subset of Patients with AML – Targeted Oncology

Older patients with acute myeloid leukemia are traditionally treated with intensive induction chemotherapy and derive benefit, but responses are not durable, and the overall survival (OS) with this treatment in short. It was hypothesized by Guillermo Garcia-Manero, MD et al, that maintenance therapy for post-remission AML might improve upon survival in the patient population, and the phase 3 QUAZAR AML-001 clinical trial was designed to investigate the hypothesis.

The oral hypomethylating agent, CC-486 induced a statistically significant improvement in OS compared with placebo in patients with AML, according to results from QUAZAR AML-001 (NCT0175753). These study findings recently drove the FDAs decision to approve the drug as a maintenance treatment for adult patients with AML who achieved a first complete remission or with incomplete blood count recovery after intensive induction chemotherapy and who are unable to complete intensive curative therapy.

The OS observed with CC-486 in QUAZAR AML-001 was 24.7 months compared with 14.8 months with placebo (HR, 0.69; 95% CI, 0.55-0.86;P=.0009). In addition to the OS benefit, relapse-free survival (RFS) was improved with CC-486 at 10.2 months compared to only 4.8 months with placebo(HR, 0.65; 95% CI, 0.52-0.81;P=.0001). During the presentation of these findings at the 2019 American Society of Hematology (ASH) Annual Meeting, the investigators concluded that CC-482 is the first agent used in the maintenance setting to show statistically significant and clinically meaningful improvements in both OS and RFS in post-remission patients with AML.

In an interview with Targeted Oncology following the FDA approval of CC-486, Dr. Garcia-Manero, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discussed the key findings from the QUAZAR AML-001 study and the importance of the FDA approval of CC-486 in post-remission AML.

TARGETED ONCOLOGY: It is known that azacitidine injection is effective for the treatment of AML, but why was is necessary to develop a new form of this drug?

Garcia-Manero: We refer to these drugs as hypomethylating agents. The issue with them is that if the patient responds to them, this requires therapy that could last for multiple months or years. We have 2 hypomethylating agents now, which are decitabine and azacitidine. The agents are usually given for five days a month or sometimes seven consecutive days a month.

This means some patients have to take IV or subcutaneous injections every week for the rest of their life.Because of this, weve been trying to develop an oral hypomethylating agent for about 50 years, and its exciting that we finally have it.

TARGETED ONCOLOGY: What was the rationale for the QUAZAR AML-001 clinical trial?

Garcia-Manero: This was a very interesting study where patients with AML that were in remission were treated in a randomized fashion with azacitadine tablets or a control. The problem with AML is relapse and there have been multiple trying this concept of maintenance therapies to see if some type of low-dose intensive chemotherapy approach would improve survival.

TARGETED ONCOLOGY: What were the key findings of the QUAZAR AML-001 study? What was the safety profile observed with CC-486 in this study?

Garcia-Manero: This is the first study where we see a survival benefit that is quite significant with the hypomethylating agent CC-486, which is a consolidation therapy approach rather than doing nothing.

The data are highly significant in terms of improvement in OS. It is close to 10 months which we have not seen in the past with almost no intervention. The only intervention performed was stem cell transplantation.

The toxicity profile of the compound was well tolerated. That said, these kinds of drugs are mild forms of chemotherapy and therefore can induce cytopenia or mild gastrointestinal toxicities.

TARGETED ONCOLOGY: Now that CC-486 is FDA approved, what will be the overall impact of this drug in the AML treatment landscape?

Garcia-Manero: Theres an interesting shift in the landscape because another oral hypomethylating agent (decitabine) was approved by the FDA last month. For CC-486, in particular, I think were going to have to decide what the role of the drug is outside its current indication of post-consolidation maintenance therapy because this CC-486 is not exactly like azacitadine, it has a different pharmacokinetic and pharmacodynamic profile. We are going to have to design new studies in AML and myelodysplastic syndrome. Right now, the role of CC-486 is clearly post-consolidation maintenance therapy.

TARGETED ONCOLOGY: How would you advise oncologists to use CC-486 in practice, now that is available?

Garcia-Manero: In my opinion, using for CC-486 in patients that have completed consolidation therapy, or who are not candidates for stem cell transplantation or had significant toxicity from consolidation, the data from QUAZAR constitute using CC-486 as the standard of care. I would advise using this maintenance approach for this patient population.

If a patient can undergo stem cell transplantation, that should be considered over CC-486. I think the future, we should also pay attention to particular genetic alterations of the patients because there may be a specific subset of patient mutated disease that may be candidates for other targeted agents instead of CC-486.

Reference:

Wei A,DohnerH, Pocock C, et al. The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation ofAzacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission.Blood .2019;134(suppl 2):LBA3.doi:10.1182/blood-2019-132405.

Read more:
CC-486 Constitutes Standard of Care for Subset of Patients with AML - Targeted Oncology

Stem Cell Therapy Market Research, Technology, Demand, Analysis, Services, Type and Global Industry Forecast 2025 | Anterogen Co., Ltd. (South Korea),…

Introducing the Stem Cell Therapy Market: Gauging the Scope This versatile research report is presenting crucial details on market relevant information, harping on ample minute details encompassing a multi-dimensional market that collectively maneuver growth in the global Stem Cell Therapy Market. This holistic report presented by the report is also determined to cater to all the market specific information and a take on business analysis and key growth steering best industry practices that optimize million-dollar opportunities amidst staggering competition in Stem Cell Therapy market. The intricately presented market report is in place to unravel all growth steering determinants, presenting a holistic overview and analytical delivery governing the realms of opportunity diversification, a thorough review of challenges and threats to plan and deliver growth driven business strategies.

Request sample copy of this report at: https://www.adroitmarketresearch.com/contacts/request-sample/691?utm_source=Pallavi

A thorough assessment of the various facets of the market including segmentation reveals that the market has been categorized into prominent segments enlisting type, technology, applications as well as end-user segments. The report illustrates a vivid diversification of the segments in order to encourage wise and remunerative business discretion in the Stem Cell Therapy market. Analysis by Type: Various fact-based details about the diverse product types are housed in this section of the report to well identify the segment that reckons high investment returns. Analysis by Application: In the successive sections of the report, readers are presented with elaborate details on various applications in accordance to end-user needs across regions.

Get a copy here: https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market?utm_source=Pallavi

Study on Table of Contents: Stem Cell Therapy Market Overview, Scope, Status and Prospect (2015-2020) covering COVID-19 Pandemic. Global Stem Cell Therapy Market Competition by Manufacturers Global Stem Cell Therapy Capacity, Production, Revenue (Value) by Region (2015-2020) Global Stem Cell Therapy Supply (Production), Consumption, Export, Import by Region (2015-2020) Global Stem Cell Therapy Production, Revenue (Value), Price Trend by Type Global Stem Cell Therapy Manufacturers Profiles/Analysis Stem Cell Therapy Manufacturing Cost Analysis Industrial Chain, Sourcing Strategy and Downstream Buyers Marketing Strategy Analysis, Distributors/Traders Global Stem Cell Therapy Market Effect Factors Analysis and Forecast (2020-2025)

Stem Cell Therapy Market Segmentation

Type Analysis of Stem Cell Therapy Market:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCs Bone Marrow-Derived Mesenchymal SCs Embryonic SCs Other Sources

Applications Analysis of Stem Cell Therapy Market:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal Disorders Wounds & Injuries Cardiovascular Diseases Gastrointestinal Diseases Immune System Diseases Other Applications

Investing in the Report: Know Why This report aims to holistically characterize and classify the Stem Cell Therapy market for superlative reader understanding A thorough evaluation to investigate material sources and downstream purchase developments are echoed in the report Elaborate references on purchaser needs, barrier analysis and opportunity assessment are also ingrained The report surveys and makes optimum forecast pertaining to market volume and value estimation

Shoot your queries here https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691?utm_source=Pallavi

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan Johnson Account Manager Global 3131 McKinney Ave Ste 600, Dallas, TX75204, U.S.A. Phone No.: USA: +1 972-362 -8199/ +91 9665341414

Go here to see the original:
Stem Cell Therapy Market Research, Technology, Demand, Analysis, Services, Type and Global Industry Forecast 2025 | Anterogen Co., Ltd. (South Korea),...

Covid-19 Impact on Global Cell Therapy Market 2020 Outlook: Industry Insights, Statistics, Shares and Forecasts to 2025 – The Daily Chronicle

Introduction & Scope: Global Cell Therapy Market

Global Cell Therapy market research report presentation demonstrates and presents an easily understandable market depiction, lending crucial insights on market size, market share as well as latest market developments and notable trends that collectively harness growth in the global Cell Therapy market. Research analysts and industry experts through this report are also aiming to lend ample light on further essential determinants such as a meticulous review and analytical take of opportunity assessment, also encompassing threat and challenge analysis that constantly deter upward growth spurt in Cell Therapy market.

Leading Companies Reviewed in the Report are:

JCR Pharmaceuticals Co., Ltd., Kolon TissueGene, Inc.; and Medipost and many more.

Get Exclusive Sample of Report on Cell Therapy market is available @ https://www.adroitmarketresearch.com/contacts/request-sample/611

Gauging COVID-19 Impact

To enable mindful business discretion amidst catastrophic developments such as COVID-19 and its subsequent implications, this ready-to-refer research report on the global Cell Therapy market is designed to answer the queries pertaining to the pandemic to emerge from catastrophic implications.

This intensively compiled research report presentation is a versatile hub of innate knowledge factors such as sales volume and bulk production, pricing matrix and sales figures, overall growth review and margin, chances of growth in the future and their range amongst other additional growth determinants that influence growth in the Cell Therapy market.

Regional Analysis

Furthermore, the report helps as a expedient guide to design and instrument probable growth routing activities across select regional hubs in the Cell Therapy market. Frontline companies and their result-based growth approaches are also recruited in the report to emulate growth.

In addition to in its succeeding sectors of the report, this detailed presentation of the Cell Therapy market offers vigorous details on regional belts and expansion projects identifying potential growth possibilities.

Quick Read Table of Contents of this Report @ https://www.adroitmarketresearch.com/industry-reports/cell-therapy-market

Global Cell Therapy Market is segmented based by type, application and region.

Based on Type, the Market has been segmented into:

By Use & Type Outlook, (Clinical-use,By Cell Therapy Type,,Non-stem Cell Therapies,Stem Cell Therapies,BM, Blood, & Umbilical Cord-derived Stem Cells,Adipose derived cells,Others), By Therapeutic Area, (Malignancies,Muscoskeletal Disorders,Autoimmune Disorders,Dermatology,Others,Research-use), By Therapy Type, (Allogenic Therapies,Autologous Therapies)

According to research inputs, this global Cell Therapy market is also likely to register a thumping growth of USD xx million in 2020 and is further anticipated to reach over xx million USD by the end of 2027, clocking at a steady CAGR of xx% through the forecast span, 2020-27. Expert opinion also suggests that the global Cell Therapy market is likely to tread on the road to recovery in the foreseeable future.

Five-Pointer Guide for Report Investment

* A rigorous, end-to-end review and analysis of the Cell Therapy market events and their implications

* A thorough compilation of broad market segments

* A complete demonstration of best in-industry practices, mindful business decisions and manufacturer activities that steer revenue sustainability in the global Cell Therapy market

* A complete assessment of competition spectrum, inclusive of relevant details about key and emerging players

* A pin-point review of the major dynamics and dominant alterations that influence growth in the global Cell Therapy market

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/611

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a Markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable Market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan Johnson Account Manager Global 3131 McKinney Ave Ste 600, Dallas, TX75204, U.S.A. Phone No.: USA: +1 972-362 -8199/ +91 9665341414

See the rest here:
Covid-19 Impact on Global Cell Therapy Market 2020 Outlook: Industry Insights, Statistics, Shares and Forecasts to 2025 - The Daily Chronicle

Stem Cell Therapy Market to Fuel Revenues Through 2020 Lake Shore Gazette – Lake Shore Gazette

Stem cells are most vital cells found in both humans and non-human animals. Stem cells are also known as centerpiece of regenerative medicine. Regenerative medicines have capability to grow new cells and replace damaged and dead cells. Stem cell is the precursors of all cells in the human body. It has the ability to replicate itself and repair and replace other damaged tissues in the human body. In addition, stem cell based therapies are used in the treatment of several chronic diseases such as cancer and blood disorders.

To remain ahead of your competitors, request for a sample here@

https://www.persistencemarketresearch.com/samples/3253

The global stem cell therapy market is categorized based on various modes of treatment and by therapeutic applications. The treatment segment is further sub-segmented into autologous stem cell therapy and allogeneic stem cell therapy. The application segment includes metabolic diseases, eye diseases, immune system diseases, musculoskeletal disorders, central nervous system disorders, cardiovascular diseases and wounds and injuries.

In terms of geographic, North America dominates the global stem cell therapy market due to increased research activities on stem cells. The U.S. represents the largest market for stem cell therapy followed by Canada in North America. However, Asia is expected to show high growth rates in the next five years in global stem cell therapy market due to increasing population. In addition, increasing government support by providing funds is also supporting in growth of the stem cell therapy market in Asia. China and India are expected to be the fastest growing stem cell therapy markets in Asia.

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/3253

In recent time, increasing prevalence of chronic diseases and increasing funds from government organizations are some of the major drivers for global stem cell therapy market. In addition, rising awareness about stem cell therapies and increasing focus on stem cell research are also supporting in growth of global stem cell therapy market. However, less developed research infrastructure for stem cell therapies and ethical issues related to embryonic stem cells are some of the major restraints for global stem cell therapy market. In addition, complexity related with the preservation of stem cell also obstructs the growth of global stem cell therapy market.

Some of the major companies operating in the global stem cell therapy market are Mesoblast Ltd., Celgene Corporation, Aastrom Biosciences, Inc. and StemCells, Inc.

You Can Request for TOC Here @ https://www.persistencemarketresearch.com/toc/3253

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved Beg Persistence Market Research Address 305 Broadway, 7th Floor, New York City, NY 10007 United States U.S. Ph. +1-646-568-7751 USA-Canada Toll-free +1 800-961-0353 Salessales@persistencemarketresearch.com Websitehttps://www.persistencemarketresearch.com

See original here:
Stem Cell Therapy Market to Fuel Revenues Through 2020 Lake Shore Gazette - Lake Shore Gazette

ERC-funded postdoctoral position at the Institut of Human Genetics, – Nature.com

The University Hospital Heidelberg is one of the major healthcare centers in Germany. Our objective is the development of innovative diagnostics and therapies as well as their quick implementation for the patient. With about 10,700 employees in more than 50 specialized clinical departments with almost 2,000 beds, about 80,000 patients in part-time and full-time inpatient treatment as well as 1,000,000 patients in ambulant treatment are medicated each year.

JobID: P0025V280

Location: Institut of Human Genetics, INF 366, 69120 Heidelberg Contract: 2 years with extension possibilities, begin as soon as possible Salary: Competitive, subject to skills and experience

The newly created Nephrogenetics unit headed by Matias Simons is looking for an enthusiastic postdoc to join our research group at the Institute of Human Genetics of the University Hospital Heidelberg. The general interest of the lab is in the molecular mechanisms underlying hereditary kidney and metabolic diseases. Most of these diseases are caused by single-gene defects and thereby offer unique opportunities to decipher fundamental regulatory pathways of human physiology and to develop targeted diagnostic and therapeutic options. Recent publications include Marchesin et al, Cell Rep 2020; Bedin et al, J Clin Invest 2019; Goncalves et al, PloS Genetics 2018; Simons, JASN 2018; Rujano et al, J Exp Med 2017; Trepiccione et al, JASN 2016; Gleixner et al, Cell Rep 2014. We combine human genetics with several experimental approaches, including fly and mouse genetics, cell culture, microscopy and biochemistry. For more info on the lab see http://www.simons-lab.de.

We offer an exciting project aimed at exploring the role of random monoallelic expression in renal development and homeostasis. For this project, we invite applications from individuals with a solid background in molecular cell biology. Prior experience with stem cells (e.g. mouse ESCs), organoids, single cell RNA-seq, epigenetics and kidney research is an advantage but not a prerequisite. The projects will be carried out in a stimulating work environment with scientific collaborations within the institute, across the Heidelberg life science community (e.g. EMBL, DKFZ) and worldwide.

The successful applicant will have good communication and organisational skills and a PhD in a relevant area (or be in the final stages of completion). We also invite applications from research-oriented MDs. Candidates are expected to be highly motivated and to work independently with a strong work ethic. As we are an international lab, profictiency in English language is a requirement. Applications including a cover letter, a detailed CV including a publication list and contacts of up to three referees should be sent as soon as possible to matias.simons@med.uni-heidelberg.de

The University Hospital Heidelberg offers:

http://www.klinikum.uni-heidelberg.de/karriere

We stand for equal opportunities. People with disabilities are given priority with the same suitability. The university hospital aims at a general increase in the proportion of women in all areas and positions where women are underrepresented. Qualified women are therefore particularly encouraged to apply.

Read the original:
ERC-funded postdoctoral position at the Institut of Human Genetics, - Nature.com